Loading
Arlocabtagene Autoleucel is an experimental CAR-T cell therapy from Juno Therapeutics, a Bristol-Myers Squibb in phase 3 trials for multiple myeloma, aimed at GPRC5D.
Arlocabtagene Autoleucel (CC-95266, BMS-986393) is a CAR-T cell therapy developed by Juno Therapeutics, a Bristol-Myers Squibb. Its target is GPRC5D (the sponsor names GPRC5D). The sponsor states: Arlocabtagene autoleucel (BMS-986393, CC-95266) is a GPRC5D-directed CAR T cell therapy, engineered to target GPRC5D-expressing myeloma cells, given as an infusion to heavily pretreated relapsed/refractory multiple myeloma patients. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06615479 (A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)), in multiple myeloma. The largest, NCT06615479, plans to enrol 440 participants with primary completion expected 2027-12-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Arlocabtagene autoleucel (BMS-986393, CC-95266) is a GPRC5D-directed CAR T cell therapy, engineered to target GPRC5D-expressing myeloma cells, given as an infusion to heavily pretreated relapsed/refractory multiple myeloma patients. Connects to GPRC5D.
1.Arlocabtagene Autoleucel slips into a pocket on GPRC5D.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Arlocabtagene Autoleucel" OR ABSTRACT:"Arlocabtagene Autoleucel" OR TITLE:"CC-95266" OR ABSTRACT:"CC-95266" OR TITLE:"BMS-986393" OR ABSTRACT:"BMS-986393" OR TITLE:"Arlo-cel" OR ABSTRACT:"Arlo-cel" OR TITLE:"GPRC5D CAR T cells" OR ABSTRACT:"GPRC5D CAR T cells") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Arlocabtagene Autoleucel, not a curated reading list.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.